An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy

@article{Sokol2016AnAO,
  title={An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy},
  author={E. Sokol and M. Karram},
  journal={Menopause},
  year={2016},
  volume={23},
  pages={1102–1107}
}
Objectives:The aim of the study was to assess the safety and efficacy of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause (GSM). Methods:Women presenting with GSM and meeting study criteria were enrolled. Examinations at baseline and follow-up (3 mo after final treatment) evaluated dilator tolerance and vaginal pH. Visual analog scales were used to assess pain, vaginal burning, vaginal itching, vaginal dryness, dyspareunia, and dysuria; Vaginal Health Index… Expand
Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes
TLDR
Based on study data up to 1 year, the fractional CO2 laser may be an effective and safe treatment for women suffering from symptoms of GSM, although additional studies with larger populations and placebo control is needed to confirm these results. Expand
Evaluation of the efficacy of fractional CO2 laser in the treatment of vulvar and vaginal menopausal symptoms
TLDR
CO2 laser treatment seems to improve the quality of life and sexual health of patients as well as GSM symptoms at 3 months of treatment; long-term reevaluation is necessary to demonstrate that improvement persists over time. Expand
Safety evaluation of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy: A prospective observational study.
TLDR
Fractional CO2 laser for treatment of VVA seems a safe therapeutic option, and patients were highly satisfied, and they would repeat laser treatment. Expand
Fractional CO2 Laser for Treatment of Vulvovaginal Atrophy: A Short Time Follow-up
TLDR
It seems vaginal fractional CO2 laser can be applied as an effective and safe treatment method in genitourinary syndrome of menopause (GSM), it is necessary to conduct studies with long-term follow-up. Expand
Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women
  • C. Arroyo
  • Medicine
  • International journal of women's health
  • 2017
TLDR
Fractional CO2 laser treatment was associated with improvement of vaginal health and amelioration of symptoms of VVA, resulting in improved sexual function in perimenopausal women. Expand
Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause.
TLDR
Fractional microablative CO2 laser treatment was associated with an improvement in symptoms of GSM and sexual function and scores on measures of sexual function, dyspareunia, and bothersomeness of sexual issues were improved from pre-treatment to long-term follow-up. Expand
Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results
TLDR
Laser therapy may provide significant improvement and/or absence of GSM symptoms up to 12 months follow-up, irrespectively to the number of laser therapies applied, in short and long-term follow- up. Expand
Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial.
TLDR
This study demonstrated that the application of microablative fractional CO2 laser was effective in treating vaginal atrophy, and could be a promising alternative treatment for postmenopausal women with vaginalatrophy. Expand
Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?
TLDR
Comparing 30 versus 40 W power of CO2 laser for the therapy of genitourinary syndrome of menopause revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. Expand
CO2-laser for the genitourinary syndrome of menopause. How many laser sessions?
TLDR
Results of this study indicate that CO2-laser therapy may contribute to complete regression of dyspareunia and dryness and reestablishment of normal sexual function in postmenopausal women, in a dose-response manner. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study
TLDR
A 12-week treatment with the fractional CO2 laser was feasible and induced a significant improvement of VVA symptoms by ameliorating vaginal health in postmenopausal women. Expand
Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser.
TLDR
Thermo-ablative fractional CO2 laser could be a safe, effective and feasible option for the treatment of VVA symptoms in post-menopausal women. Expand
Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy
TLDR
Fractional microablative CO 2 laser treatment is associated with a signifi cant improvement of sexual function and satisfaction with sexual life in postmenopausal women with VVA symptoms. Expand
Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature.
TLDR
AFP was both safe and effective for the treatment of neck laxity, rhytids and skin texture and the degree of improvement observed in wrinkling, texture and laxity after AFP coupled with the benign side effect profile has not been reported with previous trials of ablative laser resurfacing of the neck. Expand
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study
TLDR
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants. Expand
Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study
TLDR
This study shows that microablative fractional CO2 laser can produce a remodeling of vaginal connective tissue without causing damage to surrounding tissue. Expand
Fractional laser resurfacing for acne scars: a review
TLDR
This review investigates the effectiveness of ablative and nonablative fractional photothermolysis (FP) lasers for treating facial acne scars and finds that a higher proportion of patients who underwent ablative FP experienced postinflammatory hyperpigmentation (PIH) than those who hadNonablative FP. Expand
Novel Minimally Invasive VSP Er:YAG Laser Treatments in Gynecology
TLDR
Based on these initial clinical results, the new IntimaLaseTM and IncontiLase TM gynecological treatments are promising to become a minimally invasive solution of choice for many women suffering from vaginal relaxation syndrome or stress urinary incontinence. Expand
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
TLDR
Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index, decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo. Expand
Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
TLDR
Significant barriers to treatment include lack of knowledge about VVA, reluctance to discuss symptoms with HCPs, safety concerns, inconvenience, and inadequate symptom relief from available treatments. Expand
...
1
2
3
4
...